Zavesca (Miglustat) - Current Clinical Trials

Zavesca Related Clinical Trials

Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis [Active, not recruiting]

Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses [Completed]

Miglustat in Niemann-Pick Type C Disease [Active, not recruiting]

Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ? [Recruiting]

OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease [Completed]

Miglustat / OGT 918 in the Treatment of Cystic Fibrosis [Recruiting]

Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease [Recruiting]

Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2) [Completed]

Miglustat in Cystic Fibrosis [Recruiting]

Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease [Completed]

Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex [Completed]

Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3 [Completed]

Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible) [Completed]

A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV [Completed]